Sania combines precision delivery with neuromodulation to redefine the treatment of neural circuit dysfunction.

Sania Therapeutics has since been operating towards one goal: to build the safest and most effective genetic medicines that can be used to improve the quality of life for as many patients as possible. To do so, Sania applies two unique strategies to research and development: first, a “human-centric” approach where all initial stages are carried out in human cells, and second, local delivery of our therapies. This design not only maximises translation from the laboratory to the clinic, but also maximises the scope of diseases that Sania can develop therapeutics for. In this way, Sania ensures the highest levels of safety while tackling diseases with the highest unmet need. 




Founded: 2022

Arc investment: 2023


Andy Murray PhD


Akbar Dawood